The mitochondrial aspartate/glutamate carrier isoform 1 gene expression is regulated by CREB in neuronal cells

Alessio Menga, Vito Iacobazzi, Vittoria Infantino, Maria Laura Avantaggiati, Ferdinando Palmieri

A Department of Biosciences, Biotechnologies and Biopharmaceauticals, University of Bari, Via Orabona 4, 70125 Bari, Italy
b Department of Science, University of Basilicata, Via N. Sauro 85, 85100 Potenza, Italy
c Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA

1. Introduction

The mitochondrial aspartate/glutamate carrier isoform 1 (AGC1), encoded by the SLC25A12 gene, is a member of the solute carrier family 25 (SLC25A12). This transporter catalyzes an exchange between intramitochondrial aspartate and cytosolic glutamate plus a proton across the mitochondrial membrane. It plays an important role in the malate/aspartate shuttle, in urea synthesis and in gluconeogenesis from lactate. As a component of the malate/aspartate shuttle, AGC1 transfers the reducing equivalents of NADH + H+ from the cytosol into mitochondria. Two AGC isoforms, AGC1 and AGC2, are present in man; AGC1 is expressed in heart, skeletal muscle and brain, while AGC2 is expressed in many tissues, particularly in the liver (Iijima et al., 2001; Palmieri et al., 2001). AGC1 is the main AGC isoform in brain, in particular in neurons (del Arco et al., 2002; Contreras et al., 2007). Instead, the C-terminal domain of its 678-amino acid sequence contains four EF-hand Ca2+-binding sites, which were conclusively shown to bind Ca2+ in vitro and in vivo (del Arco and Satrustegui, 1998; Lasorsa et al., 2003). Through this interaction, cytosolic Ca2+ stimulates AGC1 and mitochondrial metabolism activity (Palmieri et al., 2001; Lasorsa et al., 2003; Contreras et al., 2007). Instead, the C-terminal domain of AGC1 contains six transmembrane domains and...
a characteristic mitochondrial carrier family (MCF) signature motif, like all the other members of the SLC25 or MC family (Palmieri, 2004).

Studies in animal models have highlighted the relevance of AGC1 in the physiology of neurons. AGC1 knockout mice showed a dramatic drop in brain aspartate levels, with a concomitant reduction in N-acetylaspartate (NAA) synthesis and hypomyelination (Jalil et al., 2005). The connection between lack of AGC1 and drop in NAA synthesis may due to the lack of mitochondrial aspartate output, which in turn would limit availability of NAA-derived acetate needed for lipid biosynthesis resulting in hypomyelination. Numerous studies have indeed demonstrated that acetate moieties of NAA are incorporated into brain lipids during the development of the central nervous system, hence strongly suggesting that AGC1 may be crucially involved in the myelination process (D’Adamo and Yatsu, 1966; D’Adamo et al., 1968; Patel and Clark, 1979; Burri et al., 1991; Mehta and Namboodiri, 1995; Chakraborty et al., 2001; Ledeen et al., 2006; Namboodiri et al., 2006; Moffett et al., 2013). In support of this conclusion, children harboring mutations of the SLC25A12 gene display severe developmental delay, epilepsy, hypotonia hallmarked by hypomyelination and decreased NAA in the brain (Wibom et al., 2009; Falk et al., 2014). The chromosomal region containing the gene encoding AGC1 has also been identified as a putative autism susceptibility locus (Ramos et al., 2004; Turunen et al., 2008; Palmieri et al., 2010). In addition, interest in the involvement of mitochondria in neurodegenerative and neuroinflammatory disorders, such as Parkinson’s and Alzheimer’s disease, and multiple sclerosis is emerging (Lin and Beal, 2006).

Despite the well-established role of NAA in myelin biosynthesis, it is still unknown in which subcellular compartment the biosynthesis occurs. Different studies have provided evidence that the aspartate-N-acetyltransferase (Asp-NAT), the enzyme that catalyzes the biosynthesis of NAA, is localized in the mitochondria (Patel and Clark, 1979; Madhavaraao et al., 2003; Arun et al., 2009). However, other studies performed in primary neuronal cultures established that Asp-NAT is located in the endoplasmic reticulum as well (Wianne et al., 2009; Tahay et al., 2012). A colocalization was reported by other authors (Lu et al., 2004; Ariyannur et al., 2010).

The cAMP response element-binding protein (CREB) has been widely investigated as a key metabolic sensor and regulator of energetic homeostasis (Iacobazzi et al., 2005; Altarejos and Montminy, 2011). Importantly, CREB protein is also one of the major transcriptional factors that regulates the expression of genes necessary for the development and function of the nervous system and such activities require CREB binding to – and transcription regulation of genes containing the cAMP response elements (CRE) (Lonze and Ginty, 2002).

The transcriptional activity of CREB is induced through serine phosphorylation in its conserved kinase inducible domain by the cAMP-dependent protein kinase (PKA) (Sands and Palmer, 2008), Ca2+/calmodulin protein kinase (Ennslen et al., 1994), ribosomal S6 kinase (RSK) and mitogen/stress-activated kinase (MSK) families (Deak et al., 1998). Furthermore, the phosphorylation-dependent activation of CREB involves its interaction with basal transcription factors, adaptor(s), constitutive and inducible coactivators, which contribute to form a transcriptional complex (Sheng and Greenberg, 1990). Although the transport activity and the functional role of some mutations of AGC1 have been investigated, nothing is known about the molecular mechanisms of its gene expression in any cell (Palmieri et al., 2003; Lasorsa et al., 2003; Ramos et al., 2004; Jalil et al., 2005; Contreras et al., 2007; Wibom et al., 2009).

In this work we demonstrate that in neuronal cells CREB is a main activating transcription factor of AGC1 gene expression and cytosolic Ca2+ stimulates AGC1 gene expression through CREB. Furthermore, we also showed that AGC1 is down-regulated in neuroinflammation and is up-regulated in neuronal differentiation. Therefore our data provide an important link for the activation of AGC1 in physiological and pathological conditions.

2. Experimental

2.1. Construction of plasmids

To analyze the promoter of the human AGC1 gene, reporter plasmid constructs were prepared. Progressive deletion fragments of the region from −1995 to −15 bp of the AGC1 gene promoter were amplified by PCR and cloned into the pGL3 basic-luciferase (LUC) vector (Promega) upstream of the LUC gene-coding sequence as previously described (Iacobazzi et al., 2009a). The CREB expression vector (pcDNA3-CREB) was obtained by cloning the human CREB (GenBank Accession No. NM_004379.3) cDNA into the pcDNA3.1 vector (Invitrogen). The sequences of all constructs were verified by DNA sequencing.

2.2. Cell culture, RNA interference and transient transfection

Human neuroblastoma SH-SY5Y cells (ATCCID: CRL-2266) were grown as described (Infantino et al., 2013a). Transient transfection experiments were performed using FuGENE HD Transfection Reagent (Promega) and 0.5 μg of each construct reported above, as previously described (Iacobazzi et al., 2009b). LUC activity in cell extracts was measured in a 96-well plate format by using a VICTOR® multi-label plate reader (PerkinElmer, Waltham, MA, USA). The extent of transfection was normalized by β-galactosidase activity (Infantino et al., 2011). In RNA interference experiments, the specific pre-designed small interfering RNA (siRNA) targeting human CREB (s3489, Ambion) was transfected in SH-SY5Y cells (Iacobazzi et al., 2009c).

2.3. SH-SY5Y differentiation

For SH-SY5Y cell differentiation, growth medium was replaced with serum-free medium for 16 h. The cells were then stimulated with the differentiation medium consisting of serum-free medium supplemented with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma–Aldrich, St. Louis, MO, USA) and 1 mM dibutyryl-cAMP (dbcAMP; Sigma) (Deng et al., 2001). SH-SY5Y cell differentiation was monitored by evaluating cell morphology under phase-contrast microscopy and by measuring the expression levels of neuron-specific synaptophysin (SYP) and synapse-associated protein-97 (SAP97), two neuronal differentiation markers. Cells were harvested at the indicated time points and total RNA and proteins were isolated and analyzed.

2.4. Treatments

Where indicated, SH-SY5Y cells were incubated with 10 μM forskolin (Sigma) (Monaghan et al., 2008), 20 ng/ml recombinant human neuregulin-1 (NRG-1, Immuno-Tools GmbH, Friesoythe, Germany) (Echave et al., 2009), 100 nM thapsigargin (Sigma) (Pulver et al., 2004) or 10 μM 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM) (Sigma) (Petroni et al., 2013) 16 h after having been depleted of serum; 10 μM H89 (Sigma) (Monaghan et al., 2008) or 10 μg/ml STO-609 (Sigma) (Tokumitsu et al., 2002) were added 1 h prior. Cells were harvested and total RNA and proteins were isolated and analyzed.
2.5. Activating stimuli

SH-SY5Y cells were treated up to 96 h with a combination of 500 U/ml IFNγ (Immuno-Tools GmbH, Friesoythe, Germany), 1000 U/ml TNFα (Sigma–Aldrich) and 10 ng/ml IL-1β (Immuno-Tools GmbH, Friesoythe, Germany). Cells were harvested at the indicated time points and total RNA and proteins were isolated and analyzed.

2.6. Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) experiments were performed as previously reported (Iacobazzi et al., 2008). Briefly, 2 × 10^7 SH-SY5Y cells (exposed up to 72 h to 0.5 mM IBMX and 1 mM db-cAMP) were fixed by 1% formaldehyde at 37 °C for 10 min; afterwards, the cells were lysed and fragments of 400–500 bp. The chromatin was immunoprecipitated for 14–16 h at 4 °C using a specific antibody to CREB (Thermo Fisher Scientific, Catalog No. MA5-15154). After reverse cross-linking, chromatin immunoprecipitates were purified, then 2 μl of each sample was analyzed by PCR (35 cycles) using a forward primer (5’-CGTCCATGCCAATTTAGGAGCAT-3’) and a reverse primer (5’-AGTTCGACGGATCAAAAGGAC-3’) suitable to amplify the −565/−409 bp region of the AGC1 gene promoter.

2.7. Other methods

Electrophoretic mobility shift assays (EMSA) were performed according to Menga et al. (Menga et al., 2013). Briefly, a biotin 3’-end labeled DNA probe from the −531 to −511 bp region of the human AGC1 gene promoter was incubated with 10 μg of SH-SY5Y nuclear extracts (exposed up to 24 h to 0.5 mM IBMX and 1 mM db-cAMP) for 20 min at room temperature. Total RNA was extracted from 3 × 10^6 SH-SY5Y cells, and reverse transcription was performed as described previously (Infantino et al., 2007). Real-time PCR was conducted as described (Convertini et al., 2011). Assay-on-demand for human AGC1 (Hs00186535_m1) and human β-actin (4326315E) was purchased from Applied Biosystems. Western blotting analysis was performed according to Infantino et al. (2013b). Anti-AGC1 (sc-271056, Santa Cruz Biotechnology), anti-β-actin (Santa Cruz Biotechnology), anti-T-CREB, anti-P-CREB (Ser 133) (sc-101663, Santa Cruz Biotechnology), anti-SAP97 (sc-9961, Santa Cruz Biotechnology), anti-SYP (sc-9116, Santa Cruz Biotechnology) or anti-β-amyloid (sc-9129, Santa Cruz Biotechnology) antibodies were used for immunoreaction. Band intensities were analyzed densitometrically using a Fluor-S Multimager and Quantity One software (Bio-Rad). Cell viability was evaluated by the CellTiter 96™ Non-Radioactive Cell Proliferation Assay (Promega). In brief, cells were seeded onto 96-well microtiter plates and treated with siRNA targeting CREB (siCREB) for up to 72 h. After incubation, 15 μl of the Dye Solution was added to each well and the cells were incubated for 4 h at 37 °C. Subsequently, solubilization solution/stop mix (100 μl) was added to each well and the cells were incubated for 1 h at 37 °C to promote the solubilization of formazan crystals. The level of MTT formazan was determined by measuring its absorbance at 570 nm using a 96-well plate reader (VICTOR3, PerkinElmer).

2.8. Statistical analysis

All data are presented as means ± S.D. for the number of experiments indicated in each case. Statistical analysis was performed using one-way ANOVA. p-Value <0.05 was considered statistically significant.

3. Results

3.1. AGC1 expression is downregulated by inflammatory cytokines

A typical feature of neuroinflammation is the presence in neuronal cells of pro-inflammatory cytokines, such as TNFα, IFNγ and IL-1β (McGeer and McGeer, 1995; Akiyama et al., 2000; Heneka et al., 2010; Zhao et al., 2011). Therefore, we asked whether the expression of the AGC1 gene is influenced by TNFα, IFNγ and IL-1β (individually or in combination). First, we measured the expression of the Aβ peptide, a typical marker of neurodegeneration (Blanko et al., 1999; Zhao et al., 2011) after 24 and 96 h of treatment with TNFα, IFNγ and IL-1β treated and untreated cells did not show any change in AGC1 mRNA after 24 h; whereas a decrease of about 20% was observed in cells treated with combination of TNFα/IFNγ and TNFα/IFNγ/IL-1β as compared with untreated cells (Fig. 1B). A major reduction of AGC1 gene expression was found in cells treated with individual TNFα (about 30%) and IFNγ (about 40%) after 96 h. A more significant reduction (about 80%) was seen in the cytokines combination treatment as compared with untreated cells (Fig. 1C). Accordingly, Western blot analysis demonstrated a major reduction of AGC1 protein level after 96 h of TNFα/IFNγ and TNFα/IFNγ/IL-1β treatment as compared with 24-h cytokines-treated cells (Figs. 1D and E).

These data show that AGC1 protein levels are significantly down-regulated following prolonged exposure to stimuli that mimic neuroinflammation.

3.2. CREB is a main regulator of AGC1 gene expression in neuronal cells

To investigate the regulation of AGC1 gene expression in neuronal cells, different deletion fragments of the AGC1 gene promoter were amplified, cloned into the pGL3 basic-LUC vector and transiently transfected into SH-SY5Y cells. The resulting pattern of reporter LUC activity is shown in Fig. 2. Deletion of the 5’-flanking region from position −1722 bp to position −1398 bp (pGL3-C3-LUC vector) caused a decrease in reporter gene activity of about 50% as compared to the activities of the constructs pGL3-C1-LUC from −1995 bp and pGL3-C2-LUC from −1722 bp. In contrast, deletion from −1081 bp to −565 bp (pGL3-C5-LUC construct) resulted in a drastic increase (>200%) in reporter gene activity, suggesting that a strong enhancer is located within this region. Basal LUC activity was restored with deletion from −565 bp to −433 bp (pGL3-C6-LUC vector). Preliminary, the transcription start site was found at position −82 bp upstream the ATG codon. (http://dbsst.hgc.jp/index.html). To identify the transcription factors present in construct pGL3-C5-LUC that strongly activate AGC1 gene expression, an in silico analysis was performed using different programs: the TFSEARCH Program (http://www.cbrp.jp/research/dh/TFSEARCH.html), the Alibaba 2.1 (http://www.gene-regulation.com/pub/programs/alibaba2/index.html), and the LASAGNA-Search (http://biogrid-head.engr.uconn.edu/lasagna_search/). Among several potential factor-binding motifs, a CREB binding site was present at position −525 to −517 bp upstream the ATG translation codon. Because CREB is a key factor that regulates many neural functions (Lonze and Ginty, 2002), we investigated CREB transcriptional activity on the AGC1 gene by
overexpressing CREB in SH-SYSY cells. SH-SYSY cells transfected with the pcDNA3-CREB and pGL3 basic-LUC vectors harboring the C5 fragment of the AGC1 gene promoter were incubated in the presence or absence of forskolin, an activator of adenylate cyclase (Monaghan et al., 2008). LUC activity was enhanced by about 35% in cells transfected with the pcDNA3-CREB and pGL3-C5-LUC vectors as compared to cells transfected with the pGL3-C5-LUC vector alone used as control (Fig. 3A). Forskolin added to SH-SYSY cells transfected with the pGL3-C5-LUC vector alone increased reporter activity by about 100% and to cells transfected with both the pGL3-C5-LUC and pcDNA3-CREB vectors by about 200%, as compared to control (Fig. 3A). Furthermore, forskolin-mediated increase of the reporter activity was strongly reduced by H89, a PKA inhibitor (Monaghan et al., 2008) (Fig. 3A). In contrast, LUC activity was not affected by expression of CREB or by forskolin when the control construct pGL3-C6-LUC (without the CREB binding site of the AGC1 gene promoter) was used instead of construct pGL3-C5-LUC. The results of these luciferase assays were further corroborated by monitoring the levels of the AGC1 mRNA with real-time PCR (Fig. 3B). Furthermore, to demonstrate the involvement of CREB, in its active form, in the regulation AGC1 gene expression, we compared the levels of phosphorylated CREB (P-CREB) protein relative to total CREB (T-CREB) and AGC1 protein expression. This analysis showed that AGC1 and P-CREB progressively and simultaneously increased as a consequence of both CREB overexpression and treatment with forskolin alone or in combination (Fig. 3C and quantified in Fig. 3D). Significantly, the addition of H89 abolished any of these increasing effects (Fig. 3C). The analysis of the relative ratio of P-CREB versus T-CREB with densitometry further indicated that forskolin specifically induced the accumulation of the active phosphorylated form of CREB. Specifically, P-CREB increased progressively of 50, 100 and 150%, in presence of pcDNA3-CREB, forskolin, and forskolin/pDNA3-CREB, respectively, relative to untreated cells (Fig. 3D). All of the above-reported
results provide evidence for a direct involvement of active, phosphorylated CREB in the regulation of AGC1 expression in SH-SY5Y cells.

3.3. The decrease in AGC1 expression in neuroinflammation is most likely caused by the downregulation of CREB

Having established that CREB is a main regulator of AGC1 expression, we asked whether the decrease in AGC1 expression induced by the pro-inflammatory cytokines might be due to a decrease in CREB expression. To this end, SH-SY5Y cells were treated with TNFα, IFNγ and IL-1β individually or in combination for 24 and 96 h; then cell lysates were prepared for immunoblot analysis of the cellular P-CREB and T-CREB content. When SH-SY5Y were exposed to individual cytokines for 24 h no effect was found on P-CREB and T-CREB (Fig. 4A), as confirmed also by densitometric analysis (Fig. 4B). A reduction of P-CREB and T-CREB protein (20%) was evident only in the treatment with combination of cytokines after 24 h (Fig. 4A and B). Both P-CREB and T-CREB decreased significantly (40 and 30%, respectively), after 96 h of treatment with TNFα and/or IFNγ alone. A dramatic decrease (70%) was observed upon treatment with combination of cytokines, TNFα+IFNγ and TNFα+IFNγ+IL-1β (Fig. 4C and D). No effect was evident upon IL-1β treatment. This reduction of CREB expression is fully consistent with previous reports showing that chronic exposure to TNFα, IFNγ, IL-1β, decreases CREB expression (Jambal et al., 2003). Furthermore, Aβ accumulation was shown to be inversely correlated with CREB levels in the brain of patients with Alzheimer Disease (Pugazhenthi et al., 2011). Other studies also reported that CREB-mediated expression of brain-derived neurotrophic factor (BDNF), B-cell lymphoma (Bcl-2) and baculovirus inhibitor of apoptosis proteins repeat-containing proteins (BIRC) 3 and 4 is impaired in neuroinflammation (Pugazhenthi et al., 2011). On this bases we argue that the decrease in CREB content induced by TNFα/IFNγ and TNFα/IFNγ/IL-1β could be likely linked to the reduction of AGC1 expression in neuroinflammation. However, at present other factors cannot be excluded to be involved in gene downregulation in neuroinflammation.
Cytosolic Ca\(^{2+}\) level affects AGC1 gene expression via CREB

Because Ca\(^{2+}\) is a well-known CREB inducer (Sheng and Greenberg, 1990) and is also known to stimulate AGC1 activity (Palmieri et al., 2001; Lasorsa et al., 2003; Contreras et al., 2007), we investigated whether alterations in the pool of intracellular Ca\(^{2+}\) affect AGC1 gene expression. The influence of intracellular Ca\(^{2+}\) on AGC1 gene expression was studied by using two Ca\(^{2+}\) modulators: BABTA-AM, a calcium chelator that penetrates live cells and decreases intracellular Ca\(^{2+}\) concentration (Petroni et al., 2013), and thapsigargin, which causes an increase in cellular Ca\(^{2+}\) level by inhibiting the (sarco) endoplasmatic reticulum Ca\(^{2+}\)-ATPase (SERCA) (Pulver et al., 2004). SH-SYSY cells were transfected with the pGL3-C5-LUC construct and incubated with 10 \(\mu\)M BABTA-AM for 3 h or 100 nM thapsigargin for 6 h. Because of its toxicity, it was not possible to prolong treatment with BAPTA-AM for more than 3 h (data not shown). BAPTA-AM decreased LUC activity by about 40%, whereas thapsigargin increased it by about 80% (Fig. 5A). Notably, when the cells were transfected with the reporter luciferase construct lacking the CREB binding site, the luciferase activity was negligible (Fig. 5A), thus strongly arguing that Ca\(^{2+}\) acts via CREB. The involvement of Ca\(^{2+}\) in the induction of AGC1 through CREB was further demonstrated by using STO-609, a selective inhibitor of Ca\(^{2+}\)/calmodulin-dependent protein kinase kinase (CaM-KK) (Tokumitsu et al., 2002). RT-PCR and Western blot showed that both AGC1 mRNA and protein levels were reduced by BAPTA-AM, by CREB silencing and by STO-609, but they were increased by thapsigargin and by combination of thapsigargin with pcDNA3-CREB (Fig. 5B and C). The pre-incubation with STO-609 significantly inhibited AGC1 mRNA and protein levels induced by thapsigargin and thapsigargin/pcDNA3-CREB (Fig. 5B and C). Consistently, P-CREB levels mirrored AGC1 expression. In fact, phosphorylated CREB increased significantly when intracellular Ca\(^{2+}\) was enhanced (thapsigargin) and CREB was overexpressed in presence of thapsigargin while it was reduced when Ca\(^{2+}\) was blocked by BAPTA-AM, when Ca\(^{2+}\)/calmodulin-dependent protein kinase kinase (CaM-KK) was inhibited by STO-609 and when CREB was silenced (Fig. 5C and 5D). T-CREB increased only in presence of CREB overexpressing plasmid. Of note, in presence of BAPTA, T-CREB content was unaffected whereas P-CREB decreased suggesting the Ca\(^{2+}\) signaling pathway in the activation of CREB. We next tested the effect of siCREB on cell viability and growth was tested (Fig. S1). In another set of experiments AGC1 gene expression was investigated in conditions in which the levels of cellular N-acetylaspartate is increased by treatment with neuregulin-1, a key regulator of the myelination process (Birchmeier and Nave, 2008), which triggers an increase of intracellular Ca\(^{2+}\) mediated by phospholipase C-\(\gamma\). When SH-SYSY cells were transfected with pGL3-C5-LUC construct in the presence of neuregulin (20 ng/ml) a significant increase of LUC activity was observed, whereas in the presence of BAPTA the activation was abolished. Accordingly, neuregulin-1 also increased the amount of AGC1 transcript and protein levels. As expected, BAPTA-AM abolished this up-regulation, further suggesting the involvement of Ca\(^{2+}\) in the induction of AGC1 expression (Fig. S2). Viewed together these results provide the first evidence that the levels of intracellular Ca\(^{2+}\) play a key role in regulation of AGC1 gene promoter activity, transcript and protein expression. Furthermore, the finding that AGC1 is also induced by neuregulin is fully consistent with the
A. Menga et al. / The International Journal of Biochemistry & Cell Biology 60 (2015) 157–166

Fig. 5. Effect of Ca2+ dysregulation on AGC1 expression. (A) SH-SY5Y cells transfected with pGL3-LUC constructs containing (C5) or not (C6) the CREB binding site were treated with 100 nM thapsigargin for 6 h or 10 μM BAPTA-AM for 3 h and then assayed for LUC expression activity. Data are expressed as means ± S.D. of five duplicate independent experiments. *P < 0.05, versus control (one-way ANOVA). (B) AGC1 mRNA from SH-SY5Y cells exposed to the following treatment: 3 h with 100 nM thapsigargin or 10 μM BAPTA-AM, transfection with pcDNA3-CREB and or with siCREB for 48 h and treated with 100 nM thapsigargin, preincubation with 10 μg/ml STO-609 for 1 h followed by addition of 100 nM thapsigargin and, where indicated, by pcDNA3-CREB were quantified by real-time PCR. Data are expressed as means ± S.D. of five duplicate independent experiments. *P < 0.05, **P < 0.01 (one-way ANOVA). (C) AGC1, P-CREB, T-CREB and β-actin proteins of SH-SY5Y cells treated as above. P-CREB blot was reprobed for T-CREB quantification, (B) were quantified by Western blotting. A representative of four blots is shown. (D) The intensities of P-CREB and T-CREB in (C) were analyzed densitometrically using a Fluor-S Multigrammer and Quantity One software (Bio-Rad) and corrected for β-actin. Data are expressed as means ± S.D. of four individual experiments. *P < 0.05, **P < 0.01, versus untreated control.

proposed role of this transporter in myelination and further suggest that such activity is also dependent upon Ca2+.

Supplementary Figs. S1 and S2 related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.biocel.2015.01.004.

3.5. CREB induces AGC1 gene expression during SH-SY5Y cell differentiation

Since neurite outgrowth and differentiation require an increase in energy production (Cheng et al., 2010) and AGC1 is one of the most enriched proteins during neuronal cell differentiation (Watkins et al., 2008), we next asked whether AGC1 expression changes during differentiation of SH-SY5Y cells induced by the IBMX + db-cAMP combination (Deng et al., 2001) as inducer of the CREB pathway. SH-SY5Y cell differentiation was induced with 500 μM IBMX + 1 mM db-cAMP. Successful differentiation was confirmed by the increase of neuronal markers SAP97 and SYP assayed by immunoblot analysis (Fig. 6A). Real-time PCR performed on mRNA extracted from IBMX + db-cAMP-treated cells showed a significant increase of AGC1 mRNA level up to 3 h of incubation (>100%) followed by a progressive decline until 72 h (Fig. 6B). Conversely, immunoblot analysis performed on extracts derived from SH-SY5Y cells during differentiation showed an increase in AGC1 expression level after 6 h, which remained elevated for 72 h (Fig. 6C), suggesting a different mechanism of regulation for AGC1 transcription and translation. P-CREB and T-CREB immunoblots and densitometric quantification revealed that P-CREB increased and reached its maximum (>200%) for the first 3 h subsequently followed by progressive decrease; whereas T-CREB content was unchanged over the time (Fig. 6D and E). Of note, the levels of P-CREB mirrored the AGC1 transcript profile (Fig. 6B). To determine whether these changes were reflected in a time-dependent differential recruitment of CREB on its DNA-binding consensus sites during differentiation, we performed Electromobility Shift Assays (EMSA) and Chromatin immunoprecipitation experiments (ChIP). For the formers, cellular lysates derived from IBMX and db-cAMP-treated SH-SY5Y cells were prepared at 1, 3, 6 and 24 h and incubated with a biotinylated probe containing the CREB binding site of the AGC1 promoter. In agreement with the results of real time PCR (Fig. 6B), the activation of CREB binding activity was maximally stimulated within 3 h after IBMX + db-cAMP treatment, (Fig. 6F). In full agreement with the results obtained with EMSA, the ChIP assays similarly demonstrated optimal CREB DNA binding activity on the endogenous promoter following 3 h of induction of differentiation. After this time, a progressive reduction of CREB binding was evident for up to 72 h, likely as a consequence of a reduction of P-CREB level (Fig. 6G). In summary, our results show that CREB is actively involved in AGC1 expression during SH-SY5Y cell differentiation.

4. Discussion

In the present study, we have identified for the first time a regulatory element within the human AGC1 gene promoter (comprised within 565–433 bp) that contains a CRE site and whose activity is exquisitely regulated by CREB during physiological and
pathological signals. Among the reported results the following supporting evidence can be mentioned. In neuronal SH-SY5Y cells the overexpression of CREB enhances gene reporter expression activity. Vice versa silencing of CREB reduces gene reporter activity. Consistently, the levels of both AGC1 transcript and protein were increased by overexpression of CREB and decreased by CREB knock-down.

Our data also provide evidence that the CREB-induced activation of AGC1 gene transcription in SH-SY5Y cells is accomplished by two known mechanisms leading to phosphorylation of CREB: the cAMP-dependent protein kinase pathway and the Ca²⁺ signaling to CREB pathway. The relevance of the cAMP-protein kinase pathway in the regulation of AGC1 gene transcription is demonstrated by the observation that forskolin, an activator of adenylate cyclase (Monaghan et al., 2008), increases, and H89, an inhibitor of the cAMP-dependent protein kinase pathway (Monaghan et al., 2008), decreases the luciferase reporter activity, AGC1 mRNA and AGC1 protein levels. The role of Ca²⁺ signaling via the CREB pathway is further demonstrated by the inhibition of AGC1 gene expression and protein levels by BAPTA-AM, which reduces intracellular Ca²⁺ (Petroni et al., 2013), as well as by its activation by thapsigargin, which raises cytosolic Ca²⁺ (Pulver et al., 2004), and by inhibition of Ca²⁺/calmodulin-dependent protein kinase-kinase [which inhibits the phosphorylation of CaMKIV pathway (Tokumitsu et al., 2002)]. Furthermore, when CREB was silenced, changing intracellular Ca²⁺ had no effect on AGC1 mRNA and protein. Therefore, cytosolic Ca²⁺ regulates not only the activity of AGC1 by reacting with the EF-hand Ca²⁺ binding sites present in the AGC1 N-terminal domain as previously shown (Palmieri et al., 2001; Lasorsa et al., 2003; Contreras et al., 2007), but also activates AGC1 gene expression by phosphorylating CREB. Interestingly, the higher levels of AGC1 transcript and protein, together with higher Ca²⁺ levels, in post-mortem brains from patients affected by autism as compared to control subjects (Palmieri et al., 2010; Napolioni et al., 2011) can be hypothesized to be due to a CREB-mediated increased AGC1 gene expression. Furthermore, it is likely that excessive increase in AGC1 protein
and AGC1 activity as a consequence of sustained elevation of cellular Ca²⁺ may affect global metabolism leading to oxidative stress and cellular dysfunction (Napolioni et al., 2011).

AGC1 plays an important role in the central nervous system particularly in the process of myelination through the production of NAA which is the precursor of myelin (Jalil et al., 2005; Madhava Rao et al., 2005; Wibom et al., 2009). This involvement is further showed in this study since SH-SYSY cells treated with Neuroregulin, a key regulator of myelination process, which triggers an increase of intracellular Ca²⁺ mediated by phospholipase C, up-regulated AGC1 expression. In addition, CREB, which was shown here to be a key positive transcriptional regulator of AGC1 gene expression, is known to activate transcription of target genes involved in the growth, survival and synaptic plasticity of neurons, memory, learning and mitochondrial biogenesis (Lonze and Ginty, 2002). Most of CREB-dependent genes that encode enzymes involved in energy production are down-regulated in neuroinflammation and neurodegenerative disorders (Tong et al., 2001, 2004; Saura and Valero, 2011). For these reasons, in the present study the regulation of AGC1 gene expression has been explored in neuronal cells under pathological (inflammation) and physiological (differentiation) conditions.

Oxidative stress induced by cytokines is known to play an important role in neurodegenerative process, such as in Alzheimer’s (Hensley et al., 1994; Nicolle et al., 2001). Since AGC1 is involved in energy production, in this work we evaluated the effect of cytokines, TNFα, IFNy and IL-1β, on AGC1 expression. Among the different treatments, a pronounced decrease of AGC1 mRNA and protein in neuronal cells was observed upon treatment with the combination of pro-inflammatory cytokines, TNFα and IFNy, and TNFα, IFNy and IL-1β. Of note, the cytokines-mediated down-regulation of AGC1 via CREB is exacerbated by prolonged pro-inflammatory stimuli. Although the mechanism is not known, it is very likely that oxidative stress, due to free radical generation and inflammatory responses, induces change in transcriptional events including down regulation of CREB and CREB-regulated genes. It is noteworthy that in the oxidative stress CREB decreases especially in the regions where astrocytes are abundant. Since astrocytes play an important role in neurodegeneration through release of cytokines (Wyss-Coray, 2006; Glass et al., 2010), it will be interesting to evaluate the specific AGC1 expression in this region.

Neuronal differentiation is associated with increased mitochondrial biogenesis and increased demand of metabolic energy (Cheng et al., 2010). During neuronal cell differentiation we have found a CREB-dependent activation of AGC1 gene expression. In SH-SYSY cells the level of AGC1 protein was increased after 6h of the CREB pathway induction with the IBMX + db-cAMP combination and remained elevated until 72h. The maximum increase in AGC1 transcript was reached after 3h of induction, as shown by real-time PCR, and parallels the increases of P-CREB, the binding of the DNA CRE site to nuclear extracts and the anti-CREB antibody immunoprecipitated DNA. This finding suggests that the half-life time of AGC protein is markedly high.

In conclusion, we have demonstrated that CREB regulates AGC1 gene expression in neuronal cells via PKA/Ca²⁺-mediated activation. Since AGC1 is involved in myelinoigenesis, CREB might be used as drug target to increase AGC1 gene expression in neurodegenerative diseases.

Acknowledgements

This work was supported by grants from the Ministero dell’Università e della Ricerca (MIUR), the Center of Excellence on Comparative Genomics (EGBA), the Comitato Telethon Fondazione Onlus N. GP111139, and the Universities of Bari “Aldo Moro” and Basilicata.

References

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000;21:383–421.

Alarcon JT, Montminy M. CREB and the CRTr co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 2011;12:141–51.

Ariyannur PS, Moffett JR, Manickam P, Pattabiraman N, Arun P, Nitta A, et al. Methamphetamine-induced neuronal protein NAT8L is the NAA biosynthetic enzyme: implications for a specialized acetyl coenzyme A metabolism in the CNS. Brain Res 2010;1335:1–13.

Arun P, Moffett JR, Namboodiri AM. Evidence for mitochondrial and cytoplasmic N-acetylaspartate synthesis in SH-SYSY neuroblastoma cells. Neurochem Int 2005;47(4):191–9.

Birchmeier C, Nave KA. Neuroregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 2008;56:1491–7.

Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999;13:63–8.

Burri R, Steffen C, Herschkowitz N. N-acetyl-l-asparte is a major source of acetyl groups for lipid synthesis during rat brain development. Dev Neurosci 1991;13(6):403–11.

Chakraborty G, Mekala P, Yahaya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem 2001;78:734–41.

Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. ASN Neuro 2010;2:e00045.

Couteras L, Gomez-Puertas P, Iijima M, Kobayashi K, Saheki T, Satruestegui J. Ca²⁺ Activation kinetics of the two aspartate/glutamate mitochondrial carriers, aralar and citrin: role in the heart malate–aspartate NADH shuttle. J Biol Chem 2007;282:7098–106.

Contreras L, Urbeta A, Kobayashi K, Saheki T, Satruestegui J. Low levels of citrin (SLC25A13) expression in adult mouse brain restricted to neuronal clusters. J Neurosci Res 2010;88:1009–16.

Convertti P, Infantino V, Bisaccia F, Palmieri F, Iacobazzi V. Role of FOXA and Sp1 in mitochondrial acylcarnitine carrier gene expression in different cell lines. Biochem Biophys Res Commun 2011;404:376–81.

D’Adamo AF Jr, Yatsu FM. Acetate metabolism in the nervous system. N-acetyl-l-aspartic acid and the biosynthesis of brain lipids. J Neurochem 1966;13(10):961–5.

D’Adamo AF Jr, Gidez LI, Yatsu FM. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp Brain Res 1968;5(4):267–73.

Deak M, Clifton AD, Lucoccio LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998;17:4426–41.

Del Arco A, Santurowiutz J. Molecular cloning of Astar, a new member of the mitochondrial carrier superfamily that binds calcium and is present in human muscle and brain. J Biol Chem 1997;272:23327–34.

Del Arco A, Morcillo J, Martinez-Morales JR, Calian C, Martos V, Bovolenta P, et al. Expression of the aspartate/glutamate mitochondrial carriers aralar1 and citrin during development and in adult rat tissues. Eur J Biochem 2002;269:3313–20.

Deng W, Oberroka M, Fischer I, Prokop D. In vitro differentiation of human marrow stromal cells to astrocytes. Brain Res 2010;1335:1–13.

Echave P, Machado-da-Silva G, Arkeil RS, Duchen MR, Jacobson J, Mitter R, et al. Extracellular growth factors and mitogens cooperate to drive mitochondrial biogenesis. J Cell Sci 2009;122:4516–25.

Enslen H, Sun P, Brickey D, Soderling SH, Klamo E, Soderling TR. Characterization of Ca²⁺/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. J Biol Chem 1994;269:15520–7.

Falk MJ, Li D, Gai X, McCormick E, Place E, Lasorsa FM, et al. AGC1 deficiency causes infantile epilepsy, abnormal myelination, and reduced N-acetylaspartate. JIMD Rep 2014;14:77–85.

Glauche CK, Sajo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140(6):918–34.

Heneka MT, O’Rbanon MK, Terver D, Kummer MP. Neuroinflammatory processes in Alzheimer’s disease. J Neurotranum 2010;117:919–47.

Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amylloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 1994;91(8):3270–4.

Iacobazzi V, Infantino V, Costanzo P, Izzo P, Palmieri F. Functional analysis of the promoter of the mitochondrial phosphate carrier human gene: identification of activator and repressor elements and their transcription factors. Biochem J 2005;391:613–21.

Iacobazzi V, Infantino V, Palmieri F. Epigenetic mechanisms and Sp1 regulate mitochondrial citrate carrier gene expression. Biochem Biophys Res Commun 2008;367:15–20.

Iacobazzi V, Infantino V, Bisaccia F, Castegna A, Palmieri F. Role of FOXA in mitochondrial citrate carrier gene expression and insulin secretion. Biochem Biophys Res Commun 2009a;383:220–4.
N-Acetylaspartate reductions in Canavan’s disease. Proc Natl Acad Sci USA 2005;102:5221–6.

Lu ZH, Chakraborty G, Ledeen RW, Wu G, Chakraborty G, Paiata L, Saccro R, et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Autism 2011;6:48.

Bonomi F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflug Arch 2002;444:719–28.

Palmieri F. The mitochondrial transporter family SLC25: identification, properties and pathophysiology. Mol Asp Med 2009;30:465–84.

Bonomi F, Lando E, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M, et al. Citrin and aralar1 are Ca(2+)–stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001;20:5061–9.

Nicolle MM, Gonzalez JZ, Sugaya K, Baskerville K, Bryson CL, Hirth S, et al. The mitochondrial aspartate/glutamate carrier AGC1 and calcium homeostasis: physiological links and abnormalities in autism. Mol Neurobiol 2011;44:83–92.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

Palmieri F, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M, et al. Citrin and aralar1 are Ca(2+)–stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001;20:5061–9.

Petrolini D, Tsai J, Mondal D, George W. Attenuation of low dose methylmercury and glutamate induced-cytotoxicity and tau phosphorylation by an N-methyl-D-aspartate antagonist in human neuroblastoma (SH-SYSY) cells. Environ Toxicol Pharmacol 2013;36:278–86.

H2O2-stimulated expression of the Ca(2+)-sensitive aspartate/glutamate carrier increases mitochondrial ATP production in agonist-stimulated Chinese hamster ovary cells. J Biol Chem 2003;278(1):15305–65.

Palmieri F, Pozzoli L, Papaleo V, Porcelli V, Scarcia P, Genty A, Saccro R, et al. Identification of a novel Sp1 splice variant as a strong transcriptional activator. Biochem Biophys Res Commun 2009c;386:186–91.

Tahay G, Wiame E, Tyteca D, Courtoy PJ, Van Schaftingen E. Determinants of the enzyme activity and the subcellular localization of aspartate N-acetyltransferase. J Biol Chem 1987;262:15979–83.

Zhao J, O’Connor T, Vassar R. The contribution of activated astrocytes to Aβ production in Alzheimer disease. Neurobiol Dis 2009;34:16–24.

Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12:1005–15.

Zhong Z, Wu D, Yen B, Guo Y, Li X, Li L, et al. Cytokine-mediated down-regulation of the transcription factor cAMP-responsive element-binding protein in human microglial cells. J Neuroimmunol 2011;241(1–2):84–94.

Palmieri L, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M, et al. Citrin and aralar1 are Ca(2+)–stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001;20:5061–9.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

Palmieri F, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M, et al. Citrin and aralar1 are Ca(2+)–stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001;20:5061–9.

Palmieri F. The mitochondrial transporter family SLC25: identification, properties and pathophysiology. Mol Asp Med 2013;34:465–84.

Palmieri F. The mitochondrial transporter family SLC25: identification, properties and pathophysiology. Mol Asp Med 2013;34:465–84.

Palmieri L, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M, et al. Citrin and aralar1 are Ca(2+)–stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001;20:5061–9.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.

N-Acetylaspartate synthase is required for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.